ArticleNature reviews. Drug discovery2018
Steps forward for cancer precision medicine.
Article in Nature reviews. Drug discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Activatable second-near-infrared-window multimodal luminogens with aggregation-induced-emission and aggregation-caused-quenching properties for step-imaging guided tumor therapy.Nature communications · 2025Article
- Inactivated cGAS-STING Signaling Facilitates Endocrine Resistance by Forming a Positive Feedback Loop with AKT Kinase in ER+HER2- Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Unveiling Prognostic RNA Biomarkers through a Multi-Cohort Study in Colorectal Cancer.International journal of molecular sciences · 2024Article
- Urinary detection of early responses to checkpoint blockade and of resistance to it via protease-cleaved antibody-conjugated sensors.Nature biomedical engineering · 2022Article
- Epigenetic Alterations and Mechanisms That Drive Resistance to Targeted Cancer Therapies.Cancer research · 2021Review
- Autophagy controls mesenchymal stem cell therapy in psychological stress colitis mice.Autophagy · 2021Article
- The Role of Cost-Effectiveness Analysis in Patient-Centered Cancer Care in the Era of Precision Medicine.Cancers · 2021Article
- Information, communication, and cancer patients' trust in the physician: what challenges do we have to face in an era of precision cancer medicine?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study.Frontiers in oncology · 2021Article
- SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer.Frontiers in oncology · 2021Article
- Sarcoma treatment in the era of molecular medicine.EMBO molecular medicine · 2020Review
- Current models, challenges and best practices for work conducted between European academic cooperative groups and industry.ESMO open · 2020Article
- Repositioning Lidocaine as an Anticancer Drug: The Role Beyond Anesthesia.Frontiers in cell and developmental biology · 2020Review
- An Optimal Control Framework for the Automated Design of Personalized Cancer Treatments.Frontiers in bioengineering and biotechnology · 2020Article
- CMTTdb: the cancer molecular targeted therapy database.Annals of translational medicine · 2019Article
- Optical Interrogation Techniques for Nanophotonic Biochemical Sensors.Sensors (Basel, Switzerland) · 2019Review
- Article
- Engineering Precision Medicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Review
- Visualization of drug target interactions in the contexts of pathways and networks with ReactomeFIViz.F1000Research · 2019Article
- Precise medication for tumor patients in the context of mental stress.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The availability of targeted anticancer drugs and the relative affordability of genomic analyses has led to a growing expectation among patients with cancer that they can receive personalized treatment based on the genomic signature of their tumour. Here, we discuss some of the challenges and steps needed to bring such approaches into routine practice.
Indexed as
Identifiers
29170471What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.